

Our Human Pharma Research and Development Pipeline



This represents a selection of assets under investigation in our research and development portfolio in June 2023.

>15 Potential **first-in-class assets** anchor an innovation led portfolio

>10 New **phase II and phase III starts** over the next 12-18 months

20 Potential **new therapy approvals** over the next seven years

50% Of pipeline anchored in **external collaborations***

*Across research, pre-clinical and clinical portfolios.

PHASE 1		PHASE 2		PHASE 3	
NPY2r agonist[†]	GLP-1/FGF21 agonist*	Survodutide* (BI 456906) GLP1/GCGR agonist Obesity	Survodutide* (BI 456906) GLP1/GCGR agonist NASH	Empagliflozin* / New indication** SGLT2 inhibitor Post MI	Brigimadlin* (BI 907828) MDM2-p53 DDLPS
Heart disease modulator*	B7-H6/CD3 T-cell engager*	BI 685509 sGC activator CSPH	BI 764198* TRPC6 inhibitor FSGS	BI 1015550 PDE4B inhibitor IPF	BI 1015550 PDE4B inhibitor PPF
CD137/FAP agonist*	DLL3/CD3 T-cell engager*	Empagliflozin + BI 690517 SGLT2 inhibitor + Aldosterone synthase inhibitor CKD	Brigimadlin* (BI 907828) MDM2-p53 antagonist 2L+BTC	CT-155* Prescription digital therapeutic schizophrenia	lclepertin GlyT1 inhibitor CIAS
Ezabenlimab[†] PD-1 antibody	HER2 TKI	BI 1291583 CatC inhibitor nCFB	BI 706321 Kinase inhibitor CD	REGISTRATION	
KISIMA® cancer vaccine^{††}	pan KRAS SOS1 inhibitor^{††}	BI 685509 sGC activator SSc	Spesolimab (BI 655130) IL36R antibody HS		
Brigimadlin* MDM2-p53 antagonist	SIRPα antagonist*	BI 1358894* TRPC4/5 MDD	BI 1358894* TRPC4/5 PTSD	Empagliflozin* / New indication SGLT2 inhibitor CKD	Spesolimab (BI 655130) IL36R antibody GPP flare prevention
STING agonist (2nd generation)	VSV-GP*	BI 765128 Ischemia modulator DR	BI 764524 Sema3A antibody DR	Key	
Anti-fibrotic agent*	Ion channel inhibitor			<ul style="list-style-type: none"> Cardio-Renal-Metabolic Diseases Oncology Respiratory Diseases Immunology Central Nervous System Diseases Retinal Diseases 	
Lysophospholipase inhibitor	PD-1 antibody				
TREM-1 antibody	NMDA regulator				
Phospholipid modulator	Vascular modulator				

† Being investigated in combination with other therapies.
 †† Key Pipeline Advances (January – June 2023)
 Breakthrough Therapy Designation granted by the U.S. Food and Drug Administration.
 *Partnered projects or acquired assets.
 **Prevention of HF post MI
 Fast Track Designation granted by the U.S. Food and Drug Administration

Indication abbreviations:

2L+BTC	2nd line treatment, advanced biliary tract cancer	HF	Heart failure
CD	Crohn's disease	HS	Hidradenitis suppurativa
CIAS	Cognitive impairment associated with schizophrenia	IPF	Idiopathic pulmonary fibrosis
CKD	Chronic kidney disease	MDD	Major depressive disorder
CSPH	Clinically significant portal hypertension	MI	Myocardial infarction
DDLPS	Dedifferentiated liposarcoma	NASH	Non-alcoholic steatohepatitis
DR	Diabetic Retinopathy	nCFB	non-cystic fibrosis bronchiectasis
FSGS	Focal segmental glomerulosclerosis	PPF	Progressive pulmonary fibrosis
GPP	Generalized pustular psoriasis	PTSD	Post-traumatic stress disorder
		SSc	Systemic sclerosis

CARDIO-RENAL-METABOLIC DISEASES

Building on our legacy of innovative treatments for a range of cardiovascular, renal and metabolic conditions, our R&D strategy takes a holistic view of the needs of people with metabolic diseases such as diabetes, who often have multiple, related conditions. We are pursuing the next wave of innovative medicines for obesity, kidney and liver diseases – including non-alcoholic steatohepatitis (NASH).

ONCOLOGY

We have a clear aspiration – to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. Our generational commitment to driving scientific innovation is reflected by our robust pipeline of cancer cell-directed and immuno-oncology investigational therapies, as well as the smart combination of these approaches. We are taking a diligent and broad approach, creating a collaborative research network to tap into a diversity of minds, which is vital in addressing some of the most challenging, but potentially most impactful, areas of cancer research. Simply put, for Boehringer Ingelheim, cancer care is personal, today and for generations.

RESPIRATORY DISEASES

We are building on a heritage of more than a century in respiratory diseases, with treatments in asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), systemic sclerosis-associated interstitial lung disease (SSc-ILD), and progressive fibrotic interstitial lung diseases. Our R&D approach leverages our deep understanding and extensive expertise in respiratory medicine, inflammation and fibrosis to develop the next generation of innovative therapies for patients with a broad range of lung diseases who have a high unmet medical need.

IMMUNOLOGY

Our R&D strategy is inspired by the courage of patients living with debilitating, life-limiting auto-immune conditions. We are taking bold steps to deliver scientific breakthroughs that target, repair and prevent these diseases. Specific areas of focus include inflammatory skin diseases and inflammatory bowel diseases such as Crohn's Disease and Ulcerative Colitis.

CENTRAL NERVOUS SYSTEM DISEASES

We are redefining mental health to enable people to thrive. We link behavior to the underlying neurobiology to develop targeted therapies that can ease the burden of these conditions, not just the symptoms. By combining traditional treatment with new and innovative approaches and technologies, we aim to enable those with mental health conditions to create more meaningful connections to their lives, loved ones and society.

RETINAL DISEASES

The ambition to prevent vision loss in people at risk, and preserve or restore vision in those with retinal diseases, is at the core of our R&D activities. Our extensive knowledge and insights from other therapeutic areas enable us to tackle the multifactorial pathophysiology of retinal diseases. Areas of focus include wet age-related macular degeneration, diabetic retinopathy and geographic atrophy.

In addition to building on our strengths in core therapeutic areas, we capture synergies by focusing research platforms on mechanisms such as immune modulation and fibrosis that contribute to multiple diseases. We focus expertise and resources to discover common pathophysiological mechanisms and accelerate the development of new medicines.

Our Research Beyond Borders function is exploring new frontiers in science and technology, both within and beyond our core therapeutic areas, to anticipate future trends in biomedical research and bring transformative advances to patients.

